Washington, the District Of Columbia-based Danaher Company (DHR) is a worldwide chief in science and expertise targeted on driving innovation in life sciences, diagnostics, and biotechnology. Valued at a market cap of $152.4 billion, the corporate designs, manufactures, and markets devices, consumables, and providers that help drug discovery, genomics, molecular diagnostics, and lab automation.
This healthcare firm has significantly underperformed the broader market over the previous 52 weeks. Shares of DHR have declined 8.4% over this time-frame, whereas the broader S&P 500 Index ($SPX) has gained 14.5%. Furthermore, on a YTD foundation, the inventory is down 4.4%, in comparison with SPX’s 16.5% return.
Narrowing the main focus, DHR has additionally lagged behind the iShares U.S. Healthcare ETF’s (IYH) 3.4% uptick over the previous 52 weeks and 10.3% YTD rise.
DHR’s shares rose 5.9% after it delivered its spectacular Q3 outcomes. The corporate’s income elevated 4.4% year-over-year to $6.1 billion, surpassing consensus estimates by a small margin. Furthermore, its adjusted EPS of $1.89 improved 10.5% from the year-ago quarter, topping analyst expectations of $1.71. DBS-driven execution, paired with continued momentum in its bioprocessing enterprise and better-than-anticipated respiratory income at Cepheid, contributed to its upbeat efficiency.
For the present fiscal 12 months, ending in December, analysts count on DHR’s EPS to develop 3.2% 12 months over 12 months to $7.72. The corporate’s earnings shock historical past is blended. It topped consensus estimates in three of the final 4 quarters, whereas lacking the mark on one other event.
Among the many 22 analysts overlaying the inventory, the consensus score is a “Sturdy Purchase,” which is predicated on 18 “Sturdy Purchase” and 4 “Maintain” scores.
This configuration is much less bullish than two months in the past, with 19 analysts suggesting a “Sturdy Purchase” score.
On Oct. 23, Wells Fargo & Firm (WFC) maintained an “Equal Weight” score on DHR and raised its value goal to $230, indicating a 4.8% potential upside from the present ranges.
